Higher abundance of Campylobacter in the oral microbiome of Japanese patients with moyamoya disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2023
29 10 2023
Historique:
received:
05
09
2023
accepted:
23
10
2023
medline:
31
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Genetic factors alone cannot explain the pathophysiology of moyamoya disease (MMD), and environmental factors such as an immune response are thought to be involved. Oral and gut microbiomes have attracted attention as environmental factors in the pathophysiology of some vascular and autoimmune diseases. However, the relationship between MMD and these microbiomes is yet to be thoroughly investigated. This prospective case-control study aimed to compare the microbiomes of Japanese patients with MMD with those of healthy individuals to identify the specific bacteria involved in MMD. Saliva and fecal samples were collected from 16 patients with MMD who had not undergone revascularization surgery. Fifteen healthy individuals were matched for age, sex, and body mass index. The microbiomes were determined using 16S rRNA sequencing and analyzed using QIIME2. Differentially abundant microbes were identified using LEfSE and ANCOM-BC. In the oral microbiome, the two analytical methods showed that Campylobacter was more abundant in patients with MMD than in healthy individuals. Differences in the gut microbiome were smaller than those in the oral microbiome. In conclusion, the oral microbiome profiles of patients with MMD significantly differ from those of healthy individuals. Campylobacter spp. could be a substantial environmental factor in the pathophysiology of MMD.
Identifiants
pubmed: 37899472
doi: 10.1038/s41598-023-45755-3
pii: 10.1038/s41598-023-45755-3
pmc: PMC10613609
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18545Informations de copyright
© 2023. The Author(s).
Références
mSystems. 2020 Jul 7;5(4):
pubmed: 32636335
Nature. 2021 Jun;594(7861):111-116
pubmed: 34012115
Neurol Med Chir (Tokyo). 2022 Jul 15;62(7):307-312
pubmed: 35613882
Science. 2017 Oct 20;358(6361):359-365
pubmed: 29051379
PLoS One. 2013;8(2):e56888
pubmed: 23437263
Sci Adv. 2019 Jan 23;5(1):eaau3333
pubmed: 30746447
FEMS Microbiol Rev. 2019 Jan 1;43(1):1-18
pubmed: 30219863
J Hum Genet. 2011 Jan;56(1):34-40
pubmed: 21048783
Stroke. 2022 Mar;53(3):895-903
pubmed: 34727738
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Clin Microbiol Rev. 2009 Jan;22(1):46-64, Table of Contents
pubmed: 19136433
Science. 2016 Apr 29;352(6285):560-4
pubmed: 27126039
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
Environ Health Prev Med. 2016 Mar;21(2):55-70
pubmed: 26662949
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Stroke. 1993 Dec;24(12):1960-7
pubmed: 7902623
mSphere. 2021 Oct 27;6(5):e0063621
pubmed: 34523982
Sci Rep. 2022 Nov 24;12(1):20244
pubmed: 36424438
Lancet Neurol. 2008 Nov;7(11):1056-66
pubmed: 18940695
Nat Commun. 2022 Jan 17;13(1):342
pubmed: 35039521
Stroke. 2020 Dec;51(12):3632-3639
pubmed: 33148146
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
N Engl J Med. 2009 Mar 19;360(12):1226-37
pubmed: 19297575
Nat Commun. 2020 Jul 14;11(1):3514
pubmed: 32665548
Neurosurg Focus. 2021 Sep;51(3):E3
pubmed: 34469870
Sci Rep. 2017 Feb 08;7:42421
pubmed: 28176861
PLoS Comput Biol. 2021 Nov 8;17(11):e1009581
pubmed: 34748542
PLoS One. 2011;6(7):e22542
pubmed: 21799892
BMC Bioinformatics. 2021 Oct 12;22(1):493
pubmed: 34641782
Nat Commun. 2017 Oct 10;8(1):845
pubmed: 29018189
Lancet Neurol. 2022 Aug;21(8):747-758
pubmed: 35605621